Abstract:The purposeful oblivion of the objective truth, the disregard of scientific reality, the denial of the contributions and successes of surrounding researchers, the substitution of priorities in clinical routine and the unwillingness to reason in the right direction often lead to disastrous consequences in the field of public health. Controlled projects almost never lead to a significant contribution or breakthrough in medicine that will be remembered by future generations. Another illustrative example in this regard is the link shared above to the saga of the worldwide cancer pandemic and its possible real cause: the contamination of drugs with nitrosamines/NDSRIs. The carcinogenic action of nitrosamines in rats under experimental conditions was demonstrated as early as the early 1960s (1954) by Barnes and Magee. The series of subsequent experiments in their numerous research studies was strongly indicative of a pathogenetic role of nitrosamines / dimethylnitrosamine / in the development of liver cancer and kidney cancer. Starting from the fact that contact with nitrosamines is of primary importance for the development of tumours in animals, there is practically no circumstance that would lead us to believe that the intake of the same mutagens in man would have a different carcinogenic effect from that already known to us (as was found under experimental conditions as early as 1954, but in animals). On the contrary, to this day the incidence of cancer is increasing every year and, according to global statistics, it is projected to increase by nearly 50% or 18 million new cases by 2040. The intake of (un)identified nitrosamines found in drugs as contaminants is increasing analogously to the shared breakneck cancer incidence. In addition to the number of identified carcinogens or NDSRIs, the number of affected drug classes is also progressively growing and in mid-2023 this number amounts to over 250 drugs according to the official data of the FDA bulletin of 08.04.2023. In practice, the population/patients have been in a continuous, still ongoing, multicentric prospective study since 1954. The parameters of the ˝experiment˝ are probably pre-set, crystallizing gradually over time and imposed forcefully in the form of hypnotic suggestions and directives by regulators. Encouragingly , the results of the prospective study are also available, are not one-sided and have been published in dozens of international journals as well as in part in the well-known Cancer Journal of the clinicians / Impact factor 254,7. The bad news is that in most of these observations and results, there is no correlation of what is shared between, say, 1) mandatory alternative-free intake of mutagen-contaminated drugs and 2) the breakneck development of heterogeneous cancers/including melanomas, and the scientific vision of the studies is currently rather one-sided. Cancer incidence is skyrocketing (according to Globocan/Cancer Journal for the Clinicians), and not a single worldwide study has commented on its potential link to actual contamination of the most commonly used drugs worldwide with nitrosamines/NDSRIs. For the past 5 years, the team of the Bulgarian Society of Dermatological Surgery has been committed to formalizing the final results of these prospective nationwide observational studies and providing full transparency on the relationship between the intake of actual/potential nitrosamine-contaminated drugs and the development of skin cancer. Over 95% of newly reported skin cancers during this period (2016-2023) were associated with prior intake of drugs listed in the 2023 FDA as potentially nitrosamine/NDSRIs contaminated or carcinogens. Melanoma is one of the most significant patterns of tumor arising after contact of the human body with nitrosamines. Whether the drugs affected by the contamination are from the group of sartans, beta blockers, hydrochlorothiazide, calcium antagonists, ACE inhibitors or antidepressants- the ultimate side effect remains the same and is known to the scientific community as or by the frightening and loud name : melanoma. We report the occurrence of another case of nevus associated cutaneous melanoma and multiple dysplastic nevi after taking the antidepressant Sertraline. A drug declared according to the official FDA bulletin of 08.04.2023 as potentially contaminated with class 2 nitrosamines/ NDSRIs: having similar to completely identical carcinogenic potency as that of NDMA and NNK. Or reciprocal to that in valsartan, irbesartan, olmesartan, repeatedly described already as possible melanoma inducers. According to the literature search, this is also the first case in the world of Sertraline-induced nevus associated cutaneous melanoma, and we share the view/ thesis that the real inducer of the tumor is in fact the impurities in the medication in the form of contaminants or nitrosamines: the so-called NDSRIs. The nitrosogenesis of skin cancer is a more than significant concept that has been cleverly concealed by the scientific community until recently. The reason for this concealment could be sought in the paramount importance or central role that the nitrosogenesis occupies at the base of the "pyramid" guaranteeing billions of dollars of monthly revenue to the regulators of globalism.

THE MEDICAL IMPACT OF EMERGENT BANNING OF N-NITROSODIMETHYLAMINE (NDMA)- CONTAMINATED ANTIHYPERTENSIVE DRUG: A NATIONWIDE LONGITUDINAL COHORT STUDY

Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications

Occurrence of <i>N</i>-Nitrosamines as Harmful Impurities in Pharmaceuticals

Retrospective analysis of neoplasms in patients using angiotensin receptor blockers

Permitted daily exposure limits for noteworthy N‐nitrosamines

The Association Between Environmental Exposure to Perchlorate, Nitrate, and Thiocyanate and All-Cause and Cause-Specific Mortality

Effects of the valsartan recall on heart failure patients: A nationwide analysis

Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study

Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls

Risk characterization of N- nitrosodimethylamine in pharmaceuticals

Impact of ramipril nitroso-metabolites on cancer incidence - in silico and in vitro safety evaluation

Probabilistic Health Risk Assessment of Nitrosamines in Drinking Water of Shaoxing, Zhejiang, China.

The Association Between N-nitrosamines Exposure and Lipid Metabolism in the High Incidence Area of Esophageal Cancer: A Case-Control Analysis

Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare

PBPK model-based gender-specific risk assessment of N-nitrosodimethylamine (NDMA) using human biomonitoring data

Comparison of Real-World Effectiveness Between Valsartan and Non-Ras Inhibitor Monotherapy on the Incidence of New Diabetes in Chinese Hypertensive Patients: an Electronic Health Recording System Based Study.

Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential

NITROSOGENESIS, ANTIDEPRESSANTS AND THE SERTRALIN INDUCED NEVUS ASSOCIATED CUTANEOUS MELANOMA: THE NDMA/ NNK (NDSRIS) CONTAMINATION AS MOST POTENT MELANOMA INDUCTORS: ALEA IACTA EST

Evaluation of the Regulatory Required Post-Authorization Safety Study for Propacetamol: Nested Case-Control and Case-Time-Control Studies

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system

Assessment of nitrosamine exposure in Korean foods: analysis, risk evaluation, and implications